Prevalence and nature of side effects during clozapine maintenance treatment and the relationship with clozapine dose and plasma concentration

International Clinical Psychopharmacology

Volumn 22, Issue 4, 2007, Pages 238-243

  Yusufi, Babur ^a   Mukherjee, Sujoy ^a   Flanagan, Robert ^b   Paton, Carol ^c   Dunn, Graham ^d   Page, Eleanor ^c   Barnes, Thomas R E ^c,e  

^a WEST LONDON MENTAL HEALTH NHS TRUST   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF MANCHESTER   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic Non neurological Side Effects Rating Scale score; Clozapine; Clozapine plasma concentrations; Non neurological side effects; Systematic assessment

Indexed keywords

CLOZAPINE; NORCLOZAPINE;

ADULT; AKATHISIA; ANTIPSYCHOTIC NON NEUROLOGICAL SIDE EFFECT RATING SCALE; ARTICLE; ASTHENIA; BLURRED VISION; CLINICAL TRIAL; CONCENTRATION LOSS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DAYTIME SOMNOLENCE; DRUG INDUCED HEADACHE; DYSPHORIA; FEMALE; HUMAN; HYPERSALIVATION; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; NAUSEA; NOCTURNAL ENURESIS; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PREVALENCE; PRIORITY JOURNAL; RATING SCALE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SWEATING; TACHYCARDIA; TARDIVE DYSKINESIA; VOMITING; WEIGHT GAIN;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CLOZAPINE; DISORDERS OF EXCESSIVE SOMNOLENCE; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; SIALORRHEA;

EID: 34249084616     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e32819f8f17     Document Type: Article

References (41)

1. Atkin K, Kendall F, Gould D, Freeman H, Liberman J, O'Sullivan D (1996). Neutropenia and agranulocytosis in patients receiving clozapine in the UK and Ireland. Br J Psychiatry 169:483-488.
2. Barnes TRE (1989). A rating scale for drug-induced akathisia. Br J Psychiatry 154:672-676.
3. Barnes TRE, Harvey CA (1993). Psychiatric drugs and sexuality. In: Riley AJ, Peet M, Wilson C, editors. Sexual pharmacology. Oxford: Oxford Medical Publications, pp. 176-196.
4. Barnes TRE, McPhillips MA (1999). Critical analysis and comparison of the sideeffect and safety profile of the new antipsychotics. Br J Psychiatry (Suppl 38): 34-43.
5. Bondolfi G, Morel F, Crettol S, Fady R, Bauman P, Chin B (2005). Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients. Ther Drug Monit 27:539-543.
6. Centorrino F, Baldessarini RJ, Kando JC, Frankenburg FR, Volpicelli SA, Flood JG (1994). Clozapine and metabolites: concentrations in serum and clinical findings during treatment of chronically psychotic patients. J Clin Pharmacol 14:119-125.
7. Chengappa KN, Shelton MD, Baker RW, Schooler NR, Baird J, Delaney J (1994). The prevalence of akathisia in patients receiving stable doses of clozapine. J Clin Psychiatry 55:142-145.
8. Clozapine Study Group (1993). The safety and efficacy of clozapine in severe treatment-resistant schizophrenic patients in the UK. Br J Psychiatry 163: 150-154.
9. Conley RR, Buchanan RW (1997). Evaluation of treatment-resistant schizophrenia. Schiz Bull 23:663-674.
10. Day JC, Kinderman P, Bentall R (1998). A comparison of patients' and prescribers' beliefs about neuroleptic side-effects: prevalence, distress and causation. Acta Psychiat Scand 97:93-97.
11. Derenne JL, Baldessarini RJ (2005). Clozapine toxicity associated with smoking cessation: case report. Am J Ther 12:469-471.
12. Dev VJ, Krupp P (1995). Adverse event profile and safety of clozapine. Rev Contemp Pharmacother 6:197-208.
13. Faber MS, Fuhr U (2004). Time response of cytochrome P450 1A2 activity on cessation of heavy smoking. Clin Pharmacol Ther 76:178-184.
14. Gaertner HJ, Fischer E, Hoss J (1989). Side effects of clozapine. Psychopharmacol 99:S97-S100.
15. Guy W (1976). ECDEU Assessment manual for psychopharmacology revised. Washington DC: United States Department of Health, Education and Welfare; pp. 534-537.
16. Haslemo T, Eikeseth PH, Tanum L (2006). The effect of cigarette consumption on the interaction with clozapine and olanzapine. Eur J Clin Pharmacol 62:1049-1053.
17. Honigfeld G, Patin J (1990). A two-year clinical and economic follow-up of patients on clozapine. Hosp Comm Psychiatry 41:882-885.
18. Iqbal MM, Rahman A, Husain Z (2003). Clozapine: a clinical review of adverse effects and management. Ann Clin Psychiatry 15:33-48.
19. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. (2006). Randomized controlled trial of the effect on quality of life of second- vs. first-generation antipsychotic drugs in schizophrenia: cost utility of the latest antipsychotic drugs in schizophrenia study (CUtLASS 1). Arch Gen Psychiatry 63:1079-1087.
20. Kane J, Honigfeld G, Singer J, Meltzer H (1988). Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796.
21. Khan AY, Preskorn SH (2005). Examining concentration-dependent toxicity of clozapine: role of therapeutic drug monitoring. J Psychiat Pract 11:289-301.
22. Kilian JG, Kerr K, Lawrence C (1999). Myocarditis and cardiomyopathy associated with clozapine. Lancet 354:1841-1845.
23. Kurz M, Hummer M, Oberbauer H, Fleischhacker WW (1995). Extrapyramidal side effects of clozapine and haloperidol. Psychopharmacology 118:52-56.
24. Lewis SW, Barnes TRE, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. (2006). Randomised controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schiz Bull 32:715-723.
25. Lieberman JA, Safferman AZ, Pollack S, Szymanski S, Johns C, Howard A, et al. (1994). Clinical effects of clozapine in chronic schizophrenia: response to treatment and predictors of outcome. Am J Psychiatry 151:1744-1752.
26. Marinkovic D, Timotijevic I, Babinski T, Totic S, Paunovic VR (1994). The side-effects of clozapine: a four year follow-up study. Prog Neuropsychopharmacol Biol Psychiatry 18:537-544.
27. McCarthy PT, Hughes S, Paton C (1995). Measurement of clozapine and norclozapine in serum/plasma by high performance liquid chromatography with ultraviolet detection. Biomed Chromatogr 9:36-41.
28. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. (2006). Effectiveness of clozapine versus olanzapine, quetiapine and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
29. Modestin J, Stephen P L, Erni T, Umari T (2000). Prevalence of extrapyramidal syndromes in psychiatric inpatients and the relationship of clozapine treatment to tardive dyskinesia. Schiz Res 42:223-230.
30. Naber D, Hippius H (1990). The European experience with use of clozapine. Hosp Comm Psychiatry 41:886-890.
31. Perry PJ (2001). Therapeutic drug monitoring of antipsychotics. Psychopharmacol Bull 35:19-29.
32. Perry PJ, Miller DD, Arndt SV, Cadoret RJ (1991). Clozapine and norclozapine plasma concentrations and clinical response of treatment-refractory schizophrenic patients. Am J Psychiatry 148:231-235.
33. Potkin SG, Bera R, Gulasekaran B, Costa J, Hayes S, Jin Y, et al. (1994). Serum clozapine concentrations predict clinical response in treatment-resistant schizophrenia. J Clin Psychiatry 55 (Suppl B):133-136.
34. Rostami-Hodjegan A, Amin AM, Spencer EP, Lennard MS, Tucker GT, Flanagan RJ (2004). Influence of dose, cigarette smoking, age, sex, and metabolic activity on plasma clozapine concentrations: a predictive model and nomograms to aid clozapine dose adjustment and to assess compliance in individual patients. J Clin Psychopharmacol 24:1-9.
35. Schooler NR, Kane JM (1982). Research diagnosis for tardive dyskinesia. Arch Gen Psychiatry 39:486-487.
36. Simpson GM, Angus JWS (1970). A rating scale for extrapyramidal side effects. Acta Psychiat Scand 212 (Suppl):11-19.
37. Spina E, Avenoso A, Facciola G, Scordo MG, Ancione M, Media AG, et al. (2000). Relationship between serum concentrations of clozapine and norclozapine and therapeutic response in patients with schizophrenia resistant to conventional neuroleptics. Psychopharmacology 148:83-89.
38. Tuuainen A, Wahlbeck K, Gilbody S (2002). Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomised trials. Schiz Res 56:1-10.
39. VanderZwaag C, McGee M, McEvoy JP, Freudenreich O, Wilson WH, Cooper TB (1996). Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. Am J Psychiatry 153:1579-1584.
40. Xiang YQ, Zhang ZJ, Weng YZ, Zhai YM, Li WB, Cai ZJ, et al. (2006). Serum concentrations of clozapine and norclozapine in the prediction of relapse of patients with schizophrenia. Schiz Res 83:201-210.
41. Yusufi BZ, Mukherjee S, Aitchison K, Dunn G, Page E, Barnes TRE (2005). Interrater reliability of the Antipsychotic Non-Neurological Side-Effects Rating Scale (ANNSERS). Schiz Bull 31:574.